Despite promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. These insurers are https://ellajwhk694003.ourcodeblog.com/42427535/company-s-drug-faces-is-encountering-pharmacy-benefit-manager-challenges-the-examination-of-reimbursement-fights